The pleiotropic of GLP-1/GLP-1R axis in central nervous system diseases

References

• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–2157.
   PubMed Web of Science ®Google Scholar
• Lee C, Jeon SJ, Cho KS, et al. Activation of glucagon-like peptide-1 receptor promotes neuroprotection in experimental autoimmune encephalomyelitis by reducing neuroinflammatory responses. Mol Neurobiol. 2018;55(4):3007–3020.
   PubMed Web of Science ®Google Scholar
• Vrang N, Larsen PJ. Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: Role of peripherally secreted and centrally produced peptides. Prog Neurobiol. 2010;92(3):442–462.
   PubMed Web of Science ®Google Scholar
• Cork SC, Richards JE, Holt MK, et al. Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol Metab. 2015;4(10):718–731.
   PubMed Web of Science ®Google Scholar
• Darsalia V, Ortsater H, Olverling A, et al. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. Diabetes. 2013;62(4):1289–1296.
   PubMed Web of Science ®Google Scholar
• Hunter K, Hölscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012;13(1):33.
   PubMed Web of Science ®Google Scholar
• Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci. 2002;18(1–2):7–14.
   PubMed Web of Science ®Google Scholar
• Kanoski SE, Fortin SM, Arnold M, et al. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology. 2011;152(8):3103–3112.
   PubMed Web of Science ®Google Scholar
• Kanoski SE, Rupprecht LE, Fortin SM, et al. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology. 2012;62(5–6):1916–1927.
   PubMed Web of Science ®Google Scholar
• Talbot K, Wang H-Y. The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer’s disease. Alzheimers Dement. 2014;10(1 Suppl):S12–S25.
   PubMed Web of Science ®Google Scholar
• Yun SP, Kam T, Panicker N, et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease. Nat Med. 2018;24(7):931–938.
   PubMed Web of Science ®Google Scholar
• Li Y, Perry T, Kindy MS, et al. GLP-1 Receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA. 2009;106(4):1285–1290.
   PubMed Web of Science ®Google Scholar
• Chang C, Lin T, Ho H, et al. GLP-1 analogue liraglutide attenuates mutant huntingtin-induced neurotoxicity by restoration of neuronal insulin signaling. Int J Mol Sci. 2018;19(9):2505.
   PubMed Web of Science ®Google Scholar
• Koshal P, Jamwal S, Kumar P. Glucagon-like Peptide-1 (GLP-1) and neurotransmitters signaling in epilepsy: an insight review. Neuropharmacology. 2018;136(Pt B):271–279.
   PubMed Web of Science ®Google Scholar
• Babic I, Gorak A, Engel M, et al. Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats. J Psychopharmacol. 2018;32(5):578–590.
   PubMed Web of Science ®Google Scholar
• Mayfield K, Siskind D, Winckel K, et al. Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes. J Psychopharmacol. 2016;30(3):227–236.
   PubMed Web of Science ®Google Scholar
• He W, Wang H, Zhao C, et al. Role of liraglutide in brain repair promotion through Sirt1-mediated mitochondrial improvement in stroke. J Cell Physiol. 2020;235(3):2986–3001.
   PubMed Web of Science ®Google Scholar
• Basalay MV, Davidson SM, Yellon DM. Neuroprotection in rats following ischaemia-reperfusion injury by GLP-1 analogues—liraglutide and semaglutide. Cardiovasc Drug Ther. 2019;33(6):661–667.
   PubMed Web of Science ®Google Scholar
• Gong N, Xiao Q, Zhu B, et al. Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity. J Neurosci. 2014;34(15):5322–5334.
   PubMed Web of Science ®Google Scholar
• Rehm J, Mathers C, Popova S, et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet. 2009;373(9682):2223–2233.
   PubMed Web of Science ®Google Scholar
• Jerlhag E. Gut-brain axis and addictive disorders: a review with focus on alcohol and drugs of abuse. Pharmacol Therapeut. 2019;196:1–14.
   PubMed Web of Science ®Google Scholar
• Cai H, Yang J, Wang Z, et al. Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer’s disease. Biochem Bioph Res Co. 2018;495(1):1034–1040.
   PubMed Web of Science ®Google Scholar
• Gejl M, Gjedde A, Egefjord L, et al. In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci. 2016;8:108.
   PubMed Web of Science ®Google Scholar
• Zhang S, Cai H, Ma X, et al. GLP-1 analogue CJC-1131 prevents amyloid β protein-induced impirments of spatial memory and synaptic plasticity in rats. Behav Brain Res. 2017;326:237–243.
   PubMed Web of Science ®Google Scholar
• Qi L, Ke L, Liu X, et al. Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model. Eur J Pharmacol. 2016;783:23–32.
   PubMed Web of Science ®Google Scholar
• Qiu C, Wang YP, Pan XD, et al. Exendin-4 protects Abeta(1-42) oligomer-induced PC12 cell apoptosis. Am J Transl Res. 2016;8(8):3540–3548.
   PubMed Web of Science ®Google Scholar
• Bomfim TR, Forny-Germano L, Sathler LB, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’ s disease – associated Aβ oligomers. J Clin Invest. 2012;122(4):1339–1353.
   PubMed Web of Science ®Google Scholar
• Long-Smith CM, Manning S, McClean PL, et al. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer’s disease. Neuromol Med. 2013;15(1):102–114.
   PubMed Web of Science ®Google Scholar
• Kizuka Y, Kitazume S, Fujinawa R, et al. An aberrant sugar modification of BACE1 blocks its lysosomal targeting in Alzheimer’s disease. EMBO Mol Med. 2015;7(2):175–189.
   PubMed Web of Science ®Google Scholar
• Palmigiano A, Barone R, Sturiale L, et al. CSF N-glycoproteomics for early diagnosis in Alzheimer’s disease. J Proteomics. 2016;131:29–37.
   PubMed Web of Science ®Google Scholar
• Nishikawa A, Ihara Y, Hatakeyama M, et al. Purification, cDNA cloning, and expression of UDP-N-acetylglucosamine: beta-D-mannoside beta-1,4N-acetylglucosaminyltransferase III from rat kidney. J Biol Chem. 1992;267(25):18199–18204.
   PubMed Web of Science ®Google Scholar
• Akasaka-Manya K, Manya H, Sakurai Y, et al. Protective effect of N-glycan bisecting GlcNAc residues on -amyloid production in Alzheimer’s disease. Glycobiology. 2010;20(1):99–106.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen S, Xu Z, et al. GLP-1 receptor agonists downregulate aberrant GnT-III expression in Alzheimer’s disease models through the Akt/GSK-3β/β-catenin signaling. Neuropharmacology. 2018;131:190–199.
   PubMed Web of Science ®Google Scholar
• Cao Y, Hölscher C, Hu M, et al. DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer’s disease. Eur J Pharmacol. 2018;827:215–226.
   PubMed Web of Science ®Google Scholar
• Tai J, Liu W, Li Y, et al. Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer’s disease. Brain Res. 2018;1678:64–74.
   PubMed Web of Science ®Google Scholar
• Liu W, Jalewa J, Sharma M, et al. Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Neuroscience. 2015;303:42–50.
   PubMed Web of Science ®Google Scholar
• Li L, Liu K, Zhao J, et al. Neuroprotective role of (Val(8))GLP-1-Glu-PAL in an in vitro model of Parkinson’s disease. Neural Regen Res. 2016;11(2):326–331.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen Y, Li L, et al. Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson’s disease mouse model. Behav Brain Res. 2015;293:107–113.
   PubMed Web of Science ®Google Scholar
• Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson’s disease. J Parkinsons Dis. 2014;4(3):337–344.
   PubMedGoogle Scholar
• Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481–487.
   PubMed Web of Science ®Google Scholar
• Liddelow SA, Barres BA. Reactive astrocytes: production, function, and therapeutic potential. Immunity. 2017;46(6):957–967. doi:.
   PubMed Web of Science ®Google Scholar
• Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664–1675.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang L, Li L, et al. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson’s disease mouse model. Neuropeptides. 2018;71:70–80.
   PubMed Web of Science ®Google Scholar
• Harkavyi A, Abuirmeileh A, Lever R, et al. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson’s disease. J Neuroinflammation. 2008;5(1):19.
   PubMed Web of Science ®Google Scholar
• Bertilsson G, Patrone C, Zachrisson O, et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson’s disease. J Neurosci Res. 2008;86(2):326–338.
   PubMed Web of Science ®Google Scholar
• Ji C, Xue G, Lijun C, et al. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson′s disease by increasing expression of BNDF. Brain Res. 2016;1634:1–11.
   PubMed Web of Science ®Google Scholar
• Jalewa J, Sharma MK, Gengler S, et al. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson’s disease. Neuropharmacology. 2017;117:238–248.
   PubMed Web of Science ®Google Scholar
• Hölscher C. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer’s and Parkinson’s disease models. Neuropharmacology. 2018;136:251–259.
   PubMed Web of Science ®Google Scholar
• Yuan Z, Li D, Feng P, et al. A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson’s disease. Eur J Pharmacol. 2017;812:82–90.
   PubMed Web of Science ®Google Scholar
• Feng P, Zhang X, Li D, et al. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson’s disease. NEUROPHARMACOLOGY. 2018;133(10):385–394.
   PubMed Web of Science ®Google Scholar
• Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10(4):204–216.
   PubMed Web of Science ®Google Scholar
• Novak MJU, Tabrizi SJ. Huntington’s disease: clinical presentation and treatment. Int Rev Neurobiol. 2011;98(297): 297–323.
   PubMed Web of Science ®Google Scholar
• Sayed NH, Fathy N, Kortam MA, et al. Vildagliptin attenuates huntington’s disease through activation of GLP-1 receptor/PI3K/Akt/BDNF pathway in 3-nitropropionic acid rat model. Neurotherapeutics. 2020;17(1):252–268.
   PubMed Web of Science ®Google Scholar
• Pineda JR, Canals JM, Bosch M, et al. Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington’s disease. J Neurochem. 2005;93(5):1057–1068.
   PubMed Web of Science ®Google Scholar
• Martin B, Chadwick W, Cong W, et al. Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171–82Q model of Huntington disease is related to their physiological efficacy. J Biol Chem. 2012;287(38):31766–31782.
   PubMed Web of Science ®Google Scholar
• Martin B, Golden E, Carlson OD, et al. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington’s disease. Diabetes. 2009;58(2):318–328.
   PubMed Web of Science ®Google Scholar
• Duarte AI, Sjögren M, Santos MS, Oliveira CR, et al. Dual therapy with liraglutide and ghrelin promotes brain and peripheral energy metabolism in the R6/2 mouse model of Huntington’s disease. Sci Rep. 2018;8(1):8961.
   PubMed Web of Science ®Google Scholar
• Landles C, Bates GP. Huntingtin and the molecular pathogenesis of Huntington’s disease. EMBO Rep. 2004;5(10):958–963.
   PubMed Web of Science ®Google Scholar
• de Souza DAA, de Souza AG, Chaves Filho AJM, et al. Prevention of pentylenetetrazole-induced kindling and behavioral comorbidities in mice by levetiracetam combined with the GLP-1 agonist liraglutide: Involvement of brain antioxidant and BDNF upregulating properties. Biomed Pharmacother. 2019;109:429–439.
   PubMed Web of Science ®Google Scholar
• Bozzi Y, Borrelli E. The role of dopamine signaling in epileptogenesis. Front Cell Neurosci. 2013;7:157.
   PubMed Web of Science ®Google Scholar
• Giorgi FS, Pizzanelli C, Biagioni F, et al. The role of norepinephrine in epilepsy: from the bench to the bedside. Neurosci Biobehav Rev. 2004;28(5):507–524.
   PubMed Web of Science ®Google Scholar
• Richerson GB, Buchanan GF. The serotonin axis: shared mechanisms in seizures, depression, and SUDEP. Epilepsia. 2011;52:28–38.
   PubMed Web of Science ®Google Scholar
• Koshal P, Kumar P. Neurochemical modulation involved in the beneficial effect of liraglutide, GLP-1 agonist on PTZ kindling epilepsy-induced comorbidities in mice. Mol Cell Biochem. 2016;415(1–2):77–87.
   PubMed Web of Science ®Google Scholar
• Singh D, Mishra A, Goel RK. Effect of saponin fraction from Ficus religiosa on memory deficit, and behavioral and biochemical impairments in pentylenetetrazol kindled mice. Epilepsy Behav. 2013;27(1):206–211.
   PubMed Web of Science ®Google Scholar
• Kaminski RM, Shippenberg TS, Witkin JM, et al. Genetic deletion of the norepinephrine transporter decreases vulnerability to seizures. Neurosci Lett. 2005;382(1–2):51–55.
   PubMed Web of Science ®Google Scholar
• Wen Y, Wu K, Xie Y, et al. Inhibitory effects of glucagon-like peptide-1 receptor on epilepsy. Biochem Bioph Res Co. 2019;511(1):79–86.
   PubMed Web of Science ®Google Scholar
• Wang R, Xue G, Hölscher C, et al. Post-treatment with the GLP-1 analogue liraglutide alleviate chronic inflammation and mitochondrial stress induced by Status epilepticus. Epilepsy Res. 2018;142:45–52.
   PubMed Web of Science ®Google Scholar
• Tian M, Wang R, Hölscher C, et al. The novel GLP-1/GIP dual receptor agonist DA3-CH is neuroprotective in the pilocarpine-induced epileptogenesis rat model. Epilepsy Res. 2019;154:97–106.
   PubMed Web of Science ®Google Scholar
• Mansur RB, Zugman A, Ahmed J, et al. Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders. Eur Neuropsychopharm. 2017;27(11):1153–1162.
   PubMed Web of Science ®Google Scholar
• Lach G, Schellekens H, Dinan TG, et al. Anxiety, depression, and the microbiome: a role for gut peptides. Neurotherapeutics. 2018;15(1):36–59.
   PubMed Web of Science ®Google Scholar
• Detka J, Ślusarczyk J, Kurek A, et al. Hypothalamic insulin and glucagon-like peptide-1 levels in an animal model of depression and their effect on corticotropin-releasing hormone promoter gene activity in a hypothalamic cell line. Pharmacol Rep. 2019;71(2):338–346.
   PubMed Web of Science ®Google Scholar
• Mansur RB, Lee Y, Subramaniapillai M, et al. Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists?Neuropharmacology. 2018;136(Pt B):335–342.
   PubMed Web of Science ®Google Scholar
• Mansur RB, Fries GR, Trevizol AP, et al. The effect of body mass index on glucagon-like peptide receptor gene expression in the post mortem brain from individuals with mood and psychotic disorders. Eur Neuropsychopharm. 2019;29(1):137–146.
   PubMed Web of Science ®Google Scholar
• Dixit TS, Sharma AN, Lucot JB, et al. Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis. Physiol Behav. 2013;114–115:38–41.
   PubMed Web of Science ®Google Scholar
• Kumar A, Kumar P, Pareek V, et al. Neurotrophin mediated HPA axis dysregulation in stress induced genesis of psychiatric disorders: orchestration by epigenetic modifications. J Chem Neuroanat. 2019;102:101688.
   PubMed Web of Science ®Google Scholar
• Weina H, Yuhu N, Christian H, et al. Liraglutide attenuates the depressive- and anxiety-like behaviour in the corticosterone induced depression model via improving hippocampal neural plasticity. Brain Res. 2018;1694:55–62.
   PubMed Web of Science ®Google Scholar
• Anderberg RH, Richard JE, Hansson C, et al. GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. Psychoneuroendocrinology. 2016;65:54–66.
   PubMed Web of Science ®Google Scholar
• Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder. Jama Psychiat. 2017;74(7):719.
   PubMed Web of Science ®Google Scholar
• Siskind DJ, Russell AW, Gamble C, et al. Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX). Diabetes Obes Metab. 2018;20(4):1050–1055.
   PubMed Web of Science ®Google Scholar
• Svensson CK, Larsen JR, Vedtofte L, et al. One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients. Acta Psychiatr Scand. 2019;139(1):26–36.
   PubMed Web of Science ®Google Scholar
• Sharma AN, Ligade SS, Sharma JN, Shukla P, et al. GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats. Metab Brain Dis. 2015;30(2):519–527.
   PubMed Web of Science ®Google Scholar
• During MJ, Cao L, Zuzga DS, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003;9(9):1173–1179.
   PubMed Web of Science ®Google Scholar
• Abbas T, Faivre E, Hölscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer’s disease. Behav Brain Res. 2009;205(1):265–271.
   PubMed Web of Science ®Google Scholar
• Holscher C. Synaptic plasticity and learning and memory: LTP and beyond. J Neurosci Res. 1999;58(1):62–75.
   PubMed Web of Science ®Google Scholar
• Yaffe K, Blackwell T, Kanaya AM, et al. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology. 2004;63(4):658–663.
   PubMed Web of Science ®Google Scholar
• Abdelwahed OM, Tork OM, Gamal El Din MM, et al. Effect of glucagon-like peptide-1 analogue; Exendin-4, on cognitive functions in type 2 diabetes mellitus; possible modulation of brain derived neurotrophic factor and brain Visfatin. Brain Res Bull. 2018;139:67–80.
   PubMed Web of Science ®Google Scholar
• Carvalho AL, Caldeira MV, Santos SD, et al. Role of the brain-derived neurotrophic factor at glutamatergic synapses. Br J Pharmacol. 2008;153(S1):S310–S24.
   PubMed Web of Science ®Google Scholar
• Schmitt U, Tanimoto N, Seeliger M, et al. Detection of behavioral alterations and learning deficits in mice lacking synaptophysin. Neuroscience. 2009;162(2):234–243.
   PubMed Web of Science ®Google Scholar
• Lennox R, Porter DW, Flatt PR, et al. Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice. Neuropharmacology. 2014;86:22–30.
   PubMed Web of Science ®Google Scholar
• Zanotto C, Hansen F, Galland F, et al. Glutamatergic alterations in STZ-induced diabetic rats are reversed by exendin-4. Mol Neurobiol. 2019;56(5):3538–3551.
   PubMed Web of Science ®Google Scholar
• Croxson PL, Browning PGF, Gaffan D, et al. Acetylcholine facilitates recovery of episodic memory after brain damage. J Neurosci. 2012;32(40):13787–13795.
   PubMed Web of Science ®Google Scholar
• Solmaz V, Çınar BP, Yiğittürk G, et al. Exenatide reduces TNF-α expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats. Eur J Pharmacol. 2015;765:482–487.
   PubMed Web of Science ®Google Scholar
• Bomba M, Granzotto A, Castelli V, et al. Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice. Neurobiol Aging. 2018;64:33–43.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Li Z, Cao X, et al. Exendin-4 improves behaviorial deficits via GLP-1/GLP-1R signaling following partial hepatectomy. Brain Res. 2019;1706:116–124.
   PubMed Web of Science ®Google Scholar
• Chen T, Tian P, Huang Z, et al. Engineered commensal bacteria prevent systemic inflammation-induced memory impairment and amyloidogenesis via producing GLP-1. Appl Microbiol Biotechnol. 2018;102(17):7565–7575.
   PubMed Web of Science ®Google Scholar
• Iwai T, Ito S, Tanimitsu K, et al. Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes. Neurosci Res. 2006;55(4):352–360.
   PubMed Web of Science ®Google Scholar
• Iwai T, Sawabe T, Tanimitsu K, et al. Glucagon-like peptide-1 protects synaptic and learning functions from neuroinflammation in rodents. J Neurosci Res. 2014;92(4):446–454.
   PubMed Web of Science ®Google Scholar
• Barreto-Vianna ARC, Aguila MB, Mandarim-de-Lacerda CA. Beneficial effects of liraglutide (GLP1 analog) in the hippocampal inflammation. Metab Brain Dis. 2017;32(5):1735–1745.
   PubMed Web of Science ®Google Scholar
• Teramoto S, Miyamoto N, Yatomi K, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2011;31(8):1696–1705.
   PubMed Web of Science ®Google Scholar
• Chien C, Jou M, Cheng T, et al. Exendin-4-loaded PLGA microspheres relieve cerebral ischemia/reperfusion injury and neurologic deficits through long-lasting bioactivity-mediated phosphorylated Akt/eNOS signaling in rats. J Cereb Blood Flow Metab. 2015;35(11):1790–1803.
   PubMed Web of Science ®Google Scholar
• Abdel-Latif RG, Heeba GH, Taye A, Khalifa MMA. Lixisenatide, a novel GLP-1 analog, protects against cerebral ischemia/reperfusion injury in diabetic rats. Naunyn-Schmiedeberg’s Arch Pharmacol. 2018;391(7):705–717.
   Google Scholar
• Briyal S, Shah S, Gulati A. Neuroprotective and anti-apoptotic effects of liraglutide in the rat brain following focal cerebral ischemia. Neuroscience. 2014;281:269–281.
   PubMed Web of Science ®Google Scholar
• Zhu H, Zhang Y, Shi Z, et al. The neuroprotection of liraglutide against ischaemia-induced apoptosis through the activation of the PI3K/AKT and MAPK pathways. Sci Rep-Uk. 2016;6(1):26859.
   PubMed Web of Science ®Google Scholar
• Kim S, Jeong J, Jung H, et al. Anti-inflammatory effect of glucagon like peptide-1 receptor agonist, exendin-4, through modulation of IB1/JIP1 expression and JNK signaling in stroke. Exp Neurobiol. 2017;26(4):227–239.
   PubMed Web of Science ®Google Scholar
• Yang Y, Rosenberg GA. Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke. 2011;42(11):3323–3328.
   PubMed Web of Science ®Google Scholar
• S, Pereira I, Brites D, Brito MA. Neurovascular unit: a focus on pericytes. Mol Neurobiol. 2012;45(2):327–347.
   PubMed Web of Science ®Google Scholar
• Nakagawa S, Deli MA, Kawaguchi H, et al. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int. 2009;54(3–4):253–263.
   PubMed Web of Science ®Google Scholar
• Willis CL, Leach L, Clarke GJ, et al. Reversible disruption of tight junction complexes in the rat blood-brain barrier, following transitory focal astrocyte loss. Glia. 2004;48(1):1–13.
   PubMed Web of Science ®Google Scholar
• Shin JA, Kim YA, Jeong SI, et al. Extracellular signal-regulated kinase1/2-dependent changes in tight junctions after ischemic preconditioning contributes to tolerance induction after ischemic stroke. Brain Struct Funct. 2015;220(1):13–26.
   PubMed Web of Science ®Google Scholar
• Shan Y, Tan S, Lin Y, et al. The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke. J Neuroinflamm. 2019;16(1):242.
   PubMed Web of Science ®Google Scholar
• Wiese S, Karus M, Faissner A. Astrocytes as a source for extracellular matrix molecules and cytokines. Front Pharmacol. 2012;3:120.
   PubMed Web of Science ®Google Scholar
• Argaw AT, Asp L, Zhang J, Navrazhina K, et al. Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J Clin Invest. 2012;122(7):2454–2468.
   PubMed Web of Science ®Google Scholar
• Li Y, Pan R, Qin X, et al. Ischemic neurons activate astrocytes to disrupt endothelial barrier via increasing VEGF expression. J Neurochem. 2014;129(1):120–129.
   PubMed Web of Science ®Google Scholar
• Zhang ZG, Zhang L, Jiang Q, et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest. 2000;106(7):829–838.
   PubMed Web of Science ®Google Scholar
• Chen F, Wang W, Ding H, et al. The glucagon-like peptide-1 receptor agonist exendin-4 ameliorates warfarin-associated hemorrhagic transformation after cerebral ischemia. J Neuroinflammation. 2016;13(1):204.
   PubMed Web of Science ®Google Scholar
• Asahi M, Wang X, Mori T, et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci. 2001;21(19):7724–7732.
   PubMed Web of Science ®Google Scholar
• Ou-Yang L, Liu Y, Wang BY, et al. Carnosine suppresses oxygen-glucose deprivation/recovery-induced proliferation and migration of reactive astrocytes of rats in vitro. Acta Pharmacol Sin. 2018;39(1):24–34.
   PubMed Web of Science ®Google Scholar
• Hou J, Manaenko A, Hakon J, Hansen-Schwartz J, et al. Liraglutide, a long-acting GLP-1 mimetic, and its metabolite attenuate inflammation after intracerebral hemorrhage. J Cereb Blood Flow Metab. 2012;32(12):2201–2210.
   PubMed Web of Science ®Google Scholar
• Chen F, Wang W, Ding H, et al. The glucagon-like peptide-1 receptor agonist exendin-4 ameliorates warfarin-associated hemorrhagic transformation after cerebral ischemia. J Neuroinflamm. 2016;13(1):204.
   PubMed Web of Science ®Google Scholar
• Xie Y, Wang Y, Ding H, et al. Highly glycosylated CD147 promotes hemorrhagic transformation after rt-PA treatment in diabetes: a novel therapeutic target?J Neuroinflamm. 2019;16(1):72.
   PubMed Web of Science ®Google Scholar
• Khatri R, McKinney AM, Swenson B, et al. Blood-brain barrier, reperfusion injury, and hemorrhagic transformation in acute ischemic stroke. Neurology. 2012;79(13 Suppl 1):S52–S57.
   PubMed Web of Science ®Google Scholar
• Krafft PR, Caner B, Klebe D, et al. PHA-543613 preserves blood-brain barrier integrity after intracerebral hemorrhage in mice. Stroke. 2013;44(6):1743–1747.
   PubMed Web of Science ®Google Scholar
• Taddei A, Giampietro C, Conti A, et al. Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat Cell Biol. 2008;10(8):923–934.
   PubMed Web of Science ®Google Scholar
• Liebner S, Corada M, Bangsow T, et al. Wnt/beta-catenin signaling controls development of the blood-brain barrier. J Cell Biol. 2008;183(3):409–417.
   PubMed Web of Science ®Google Scholar
• Kanazawa M, Takahashi T, Nishizawa M, et al. Therapeutic strategies to attenuate hemorrhagic transformation after tissue plasminogen activator treatment for acute ischemic stroke. J Atheroscler Thromb. 2017;24(3):240–253.
   PubMed Web of Science ®Google Scholar
• Hill MD, Buchan AM. Thrombolysis for acute ischemic stroke: results of the Canadian alteplase for stroke effectiveness study. Can Med Assoc J. 2005;172(10):1307–1312.
   PubMed Web of Science ®Google Scholar
• Rangaraju V, Lewis TL, Hirabayashi Y, et al. Pleiotropic mitochondria: the influence of mitochondria on neuronal development and disease. J Neurosci. 2019;39(42):8200–8208.
   PubMed Web of Science ®Google Scholar
• Cheng A, Hou Y, Mattson MP. Mitochondria and neuroplasticity. Asn Neuro. 2010;2(5):AN20100019.
   Web of Science ®Google Scholar
• Lin M-Y, Sheng Z-H. Regulation of mitochondrial transport in neurons. Exp Cell Res. 2015;334(1):35–44.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang X, He J, et al. Delayed administration of the glucagon-like peptide 1 analog liraglutide promoting angiogenesis after focal cerebral ischemia in mice. J Stroke Cerebrovasc Dis. 2018;27(5):1318–1325.
   PubMed Web of Science ®Google Scholar
• Dong W, Miao Y, Chen A, et al. Delayed administration of the GLP-1 receptor agonist liraglutide improves metabolic and functional recovery after cerebral ischemia in rats. Neurosci Lett. 2017;641:1–7.
   PubMed Web of Science ®Google Scholar
• Rachmany L, Tweedie D, Li Y, et al. Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. Age (Dordr). 2013;35(5):1621–1636.
   PubMedGoogle Scholar
• Li Y, Bader M, Tamargo I, et al. Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice. J Neurochem. 2015;135(6):1203–1217.
   PubMed Web of Science ®Google Scholar
• Li Y, Glotfelty EJ, Namdar I, et al. Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury. Exp Neurol. 2020;324:113113.
   PubMed Web of Science ®Google Scholar
• Bader M, Li Y, Lecca D, et al. Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury. Neurobiol Dis. 2019;124:439–453.
   PubMed Web of Science ®Google Scholar
• Fukuda S, Nakagawa S, Tatsumi R, et al. Glucagon-like peptide-1 strengthens the barrier integrity in primary cultures of rat brain endothelial cells under basal and hyperglycemia conditions. J Mol Neurosci. 2016;59(2):211–219.
   PubMed Web of Science ®Google Scholar
• Li H, Zhao X, Zhang X, et al. Exendin-4 enhances motor function recovery via promotion of autophagy and inhibition of neuronal apoptosis after spinal cord injury in rats. Mol Neurobiol. 2016;53(6):4073–4082.
   PubMed Web of Science ®Google Scholar
• Zhang D, Lv G. Therapeutic potential of spinal GLP-1 receptor signaling. Peptides. 2018;101:89–94.
   PubMed Web of Science ®Google Scholar
• Varma AK, Das A, Wallace G, et al. Spinal cord injury: a review of current therapy, future treatments, and basic science frontiers. Neurochem Res. 2013;38(5):895–905.
   PubMed Web of Science ®Google Scholar
• Rabchevsky AG, Patel SP, Springer JE. Pharmacological interventions for spinal cord injury: Where do we stand? How Might we Step Forward?Pharmacol Ther. 2011;132(1):15–29.
   PubMed Web of Science ®Google Scholar
• Zhou T, Zheng Y, Sun L, et al. Microvascular endothelial cells engulf myelin debris and promote macrophage recruitment and fibrosis after neural injury. Nat Neurosci. 2019;22(3):421–435.
   PubMed Web of Science ®Google Scholar
• Li Y, Jones JW, MC, Choi H, et al. cPLA2 activation contributes to lysosomal defects leading to impairment of autophagy after spinal cord injury. Cell Death Dis. 2019;10(7):531.
   PubMed Web of Science ®Google Scholar
• Lin J, Pan X, Huang C, et al. Dual regulation of microglia and neurons by astragaloside IV-mediated mTORC1 suppression promotes functional recovery after acute spinal cord injury. J Cell Mol Med. 2019;24(1):671–685.
   PubMed Web of Science ®Google Scholar
• Rong Y, Liu W, Wang J, et al. Neural stem cell-derived small extracellular vesicles attenuate apoptosis and neuroinflammation after traumatic spinal cord injury by activating autophagy. Cell Death Dis. 2019;10(5):340.
   PubMed Web of Science ®Google Scholar
• Sun Z, Liu Y, Kong X, et al. Exendin-4 plays a protective role in a rat model of spinal cord injury through SERCA2. Cell Physiol Biochem. 2018;47(2):617–629.
   PubMedGoogle Scholar
• Hong S, Lee J, Seo H, et al. Na+–Ca2+ exchanger targeting miR-132 prevents apoptosis of cardiomyocytes under hypoxic condition by suppressing Ca2+ overload. Biochem Bioph Res Co. 2015;460(4):931–937.
   PubMed Web of Science ®Google Scholar
• Wu H-Y, Mao X-F, Fan H, et al. p38β mitogen-activated protein kinase signaling mediates exenatide-stimulated microglial β-endorphin expression. Mol Pharmacol. 2017;91(5):451–463.
   PubMed Web of Science ®Google Scholar
• Fan H, Gong N, Li T, et al. The non-peptide GLP-1 receptor agonist WB4-24 blocks inflammatory nociception by stimulating β-endorphin release from spinal microglia. Br J Pharmacol. 2015;172(1):64–79.
   PubMed Web of Science ®Google Scholar
• Gong N, Fan H, Ma A-N, et al. Geniposide and its iridoid analogs exhibit antinociception by acting at the spinal GLP-1 receptors. Neuropharmacology. 2014;84:31–45.
   PubMed Web of Science ®Google Scholar
• Fan H, Li T-F, Gong N, et al. Shanzhiside methylester, the principle effective iridoid glycoside from the analgesic herb Lamiophlomis rotata, reduces neuropathic pain by stimulating spinal microglial β-endorphin expression. Neuropharmacology. 2016;101:98–109.
   PubMed Web of Science ®Google Scholar
• Xu M, Wu H, Liu H, et al. Morroniside, a secoiridoid glycoside fromCornus officinalis, attenuates neuropathic pain by activation of spinal glucagon-like peptide-1 receptors. Brit J Pharmacol. 2017;174(7):580–590.
   PubMed Web of Science ®Google Scholar
• Zhu B, Gong N, Fan H, et al. Lamiophlomis rotata, an orally available Tibetan herbal painkiller, specifically reduces pain hypersensitivity states through the activation of spinal glucagon-like peptide-1 receptors. Anesthesiology. 2014;121(4):835–851.
   PubMed Web of Science ®Google Scholar
• Lew L, Hor Y, Yusoff NAA, et al. Probiotic Lactobacillus plantarum P8 alleviated stress and anxiety while enhancing memory and cognition in stressed adults: a randomised, double-blind, placebo-controlled study. Clin Nutr. 2018;38(5):2053–2064.
   PubMed Web of Science ®Google Scholar
• Kong G, Cao KL, Judd LM, et al. Microbiome profiling reveals gut dysbiosis in a transgenic mouse model of Huntington’s disease. Neurobiol Dis. 2018;135:104268.
   PubMed Web of Science ®Google Scholar
• Rogers GB, Keating DJ, Young RL, et al. From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. Mol Psychiatry. 2016;21(6):738–748.
   PubMed Web of Science ®Google Scholar
• Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012;13(10):701–712.
   PubMed Web of Science ®Google Scholar
• Huang S, Chen L, Wang M, et al. Lactobacillus paracasei PS23 delays progression of age-related cognitive decline in senescence accelerated mouse prone 8 (SAMP8) mice. Nutrients. 2018;10(7):894.
   PubMed Web of Science ®Google Scholar
• Marques C, Fernandes I, Meireles M, et al. Gut microbiota modulation accounts for the neuroprotective properties of anthocyanins. Sci Rep-Uk. 2018;8(1):11341.
   PubMed Web of Science ®Google Scholar
• Li H, Sun J, Du J, et al. Clostridium butyricum exerts a neuroprotective effect in a mouse model of traumatic brain injury via the gut-brain axis. Neurogastroenterol Motil. 2018;30(5):e13260.
   PubMed Web of Science ®Google Scholar
• Sun J, Wang F, Hu X, et al. Clostridium butyricum attenuates chronic unpredictable mild stress-induced depressive-like behavior in mice via the gut-brain axis. J Agric Food Chem. 2018;66(31):8415–8421.
   PubMed Web of Science ®Google Scholar
• Yadav H, Lee J-H, Lloyd J, et al. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem. 2013;288(35):25088–25097.
   PubMed Web of Science ®Google Scholar
• Araki Y, Andoh A, Fujiyama Y, et al. Oral administration of a product derived from Clostridium butyricum in rats. Int J Mol Med. 2002;9(1):53–57.
   PubMed Web of Science ®Google Scholar
• Tolhurst G, Heffron H, Lam YS, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012;61(2):364–371.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang F, Liu S, et al. Sodium butyrate exerts protective effect against Parkinson’s disease in mice via stimulation of glucagon like peptide-1. J Neurol Sci. 2017;381:176–181.
   PubMed Web of Science ®Google Scholar
• Vallöf D, Kalafateli AL, Jerlhag E. Brain region specific glucagon-like peptide-1 receptors regulate alcohol-induced behaviors in rodents. Psychoneuroendocrinology. 2019;103:284–295.
   PubMed Web of Science ®Google Scholar
• Hernandez NS, Schmidt HD. Central GLP-1 receptors: novel molecular targets for cocaine use disorder. Physiol Behav. 2019;206:93–105.
   PubMed Web of Science ®Google Scholar
• Thomsen M, Dencker D, Wörtwein G, et al. The glucagon-like peptide 1 receptor agonist exendin-4 decreases relapse-like drinking in socially housed mice. Pharmacol Biochem Behav. 2017;160:14–20.
   PubMed Web of Science ®Google Scholar
• Jerlhag E. GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence. Neuropharmacology. 2018;136(Pt B):343–349.
   PubMed Web of Science ®Google Scholar
• Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology. 2012;153(2):647–658.
   PubMed Web of Science ®Google Scholar
• Reiner DJ, Leon RM, McGrath LE, et al. Glucagon-like peptide-1 receptor signaling in the lateral dorsal tegmental nucleus regulates energy balance. Neuropsychopharmacology. 2018;43(3):627–637.
   PubMed Web of Science ®Google Scholar
• Egecioglu E, Steensland P, Fredriksson I, et al. The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents. Psychoneuroendocrinology. 2013;38(8):1259–1270.
   PubMed Web of Science ®Google Scholar
• Suchankova P, Yan J, Schwandt ML, et al. The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence. Transl Psychiatry. 2015;5(6):e583–e583.
   PubMed Web of Science ®Google Scholar
• Sirohi S, Schurdak JD, Seeley RJ, et al. Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors. Physiol Behav. 2016;161:140–144.
   PubMed Web of Science ®Google Scholar
• Sørensen G, Reddy IA, Weikop P, Graham DL, et al. The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice. Physiol Behav. 2015;149:262–268.
   PubMed Web of Science ®Google Scholar
• Schmidt HD, Mietlicki-Baase EG, Ige KY, et al. Glucagon-like peptide-1 receptor activation in the ventral tegmental area decreases the reinforcing efficacy of cocaine. Neuropsychopharmacology. 2016;41(7):1917–1928.
   PubMed Web of Science ®Google Scholar
• Harasta AE, Power JM, von Jonquieres G, et al. Septal glucagon-like peptide 1 receptor expression determines suppression of cocaine-induced behavior. Neuropsychopharmacology. 2015;40(8):1969–1978.
   PubMed Web of Science ®Google Scholar
• Hayes MR, Schmidt HD. GLP-1 influences food and drug reward. Curr Opin Behav Sci. 2016;9:66–70.
   PubMed Web of Science ®Google Scholar
• Bouhlal S, Ellefsen KN, Sheskier MB, et al. Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses. Drug Alcohol Depend. 2017;180:68–75.
   PubMed Web of Science ®Google Scholar
• Duaso M, Duncan D. Health impact of smoking and smoking cessation strategies: current evidence. Br J Community Nurs. 2012;17(8):356–363.
   PubMedGoogle Scholar
• Kenny PJ, Markou A. Nicotine self-administration acutely activates brain reward systems and induces a long-lasting increase in reward sensitivity. Neuropsychopharmacology. 2006;31(6):1203–1211.
   PubMed Web of Science ®Google Scholar
• Egecioglu E, Engel JA, Jerlhag E, et al. The glucagon-like peptide 1 analogue exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice. PLoS ONE. 2013;8(10):e77284.
   PubMed Web of Science ®Google Scholar
• Tuesta LM, Chen Z, Duncan A, et al. GLP-1 acts on habenular avoidance circuits to control nicotine intake. Nat Neurosci. 2017;20(5):708–716.
   PubMed Web of Science ®Google Scholar
• Zhao P, Liang Y, Belousoff MJ, et al. Activation of the GLP-1 receptor by a non-peptidic agonist. Nature. 2020;577(7790):432–436.
   PubMed Web of Science ®Google Scholar
• Htike ZZ, Zaccardi F, Papamargaritis D, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19(4):524–536.
   PubMed Web of Science ®Google Scholar
• Zhang C, Kaye JA, Cai Z, et al. Area postrema cell types that mediate nausea-associated behaviors. Neuron. 2021;109(3):461–472.
   PubMed Web of Science ®Google Scholar
• Swick JC, Alhadeff AL, Grill HJ, et al. Parabrachial nucleus contributions to glucagon-like peptide-1 receptor agonist-induced hypophagia. Neuropsychopharmacology. 2015;40(8):2001–2014.
   PubMed Web of Science ®Google Scholar
• McKay NJ, Daniels D. Glucagon-like peptide-1 receptor agonist administration suppresses both water and saline intake in rats. J Neuroendocrinol. 2013;25(10):929–938.
   PubMed Web of Science ®Google Scholar